Renovaro Inc. (NASDAQ:RENB) Major Shareholder Sells $31,600.00 in Stock

Renovaro Inc. (NASDAQ:RENB) major shareholder Anderson Wittekind William sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $1.58, for a total transaction of $31,600.00. Following the transaction, the insider now owns 1,243,499 shares of the company’s stock, valued at approximately $1,964,728.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Anderson Wittekind William also recently made the following trade(s):

• On Thursday, June 27th, Anderson Wittekind William sold 14,671 shares of Renovaro stock. The shares were sold at an average price of $1.50, for a total transaction of $22,006.50.
• On Friday, June 14th, Anderson Wittekind William sold 50,000 shares of Renovaro stock. The shares were sold at an average price of $1.58, for a total transaction of $79,000.00.

Renovaro Price Performance

RENB traded down $0.07 during trading on Thursday, reaching $1.50. The company had a trading volume of 773,678 shares, compared to its average volume of 496,393. Renovaro Inc. has a 12 month low of $0.39 and a 12 month high of $5.25. The business’s fifty day moving average price is $1.46 and its 200 day moving average price is $2.63. The company has a market cap of $221.27 million, a P/E ratio of -2.07 and a beta of 0.44.

Renovaro (NASDAQ:RENB) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.08) earnings per share for the quarter.

Institutional Trading of Renovaro

A number of institutional investors have recently made changes to their positions in RENB. SG Americas Securities LLC bought a new stake in shares of Renovaro in the first quarter worth $46,000. Vanguard Group Inc. lifted its position in shares of Renovaro by 904.0% in the first quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock worth $10,379,000 after purchasing an additional 3,526,565 shares in the last quarter. Finally, Tidal Investments LLC bought a new stake in shares of Renovaro in the first quarter worth $98,000. Institutional investors own 71.41% of the company’s stock.

About Renovaro

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.